Stein, Maike
Hoffmann, Sarah
Gerischer, Lea
Stascheit, Frauke
Legg, David
Meisel, Andreas
Lehnerer, Sophie
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 3 July 2022
Accepted: 16 November 2022
First Online: 7 December 2022
Declarations
:
: A declaration of informed consent to participate was not necessary due to retrospective analysis as approved by the ethics committee of Charité – Universitätsmedizin Berlin. This project received ethics approval by the institutional ethics committee of Charité – Universitätsmedizin Berlin (reference EA1/229/21). The study was conducted in accordance with the declaration of Helsinki and was registered on DRKS (DRKS00028067).
: Not applicable.
: M.S. received speaker’s honoraria for attendance at patient events from Argenx. S.H. received speaker’s honoria from Alexion and Argenx, and honoria for attendance at advisory boards from Alexion. S.L. received speaker’s honoraria and honoraria for attendance at advisory boards from Alexion and Argenx. F.S. received speaker’s honoria and honoria for attendance at advisory boards from Alexion. A.M. received speaker’s honoraria from Alexion, Grifols and Hormosan. A.M. received honoraria from Alexion, UCB, MorphoSys and Argenx for consulting services and financial research support from Octapharma and Alexion. A.M. is chairman of the medical advisory board of the German Myasthenia Gravis Society. All other authors report no disclosures relevant to the manuscript.